证券代码：000504 证券简称：*ST 生物 公告编号：2026-013 南华生物医药股份有限公司 2. 根据《深圳证券交易所股票上市规则（2025 年修订）》第 9.3.6 条的规 定：上市公司因触及本规则第 9.3.1 条第一款第一项至第三项情形，其股票交易 被实施退市风险警示后，应当在其股票交易被实施退市风险警示当年会计年度结 束后一个月内，披露股票可能被终止上市的风险提示公告，在首次风险提示公告 披露后至年度报告披露前，每十个交易日披露一次风险提示公告。敬请广大投资 者理性投资，注意风险。 公司可能触及的终止上市情形： | 具体情形 | 是否适用 （对可能触及的打勾） | | --- | --- | | 经审计的利润总额、净利润、扣除非经常性损益后 | | | 的净利润三者孰低为负值，且扣除后的营业收入低 | √ | | 于 3 亿元。 | | | 经审计的期末净资产为负值。 | | 1 股票可能被终止上市的第四次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 特别提示： 1. 南华生物医药股份有限公司（以下简称"公司"）2024 年 ...

南华生物医药股份有限公司 股票可能被终止上市的第三次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 特别提示： 1. 南华生物医药股份有限公司（以下简称"公司"）2024 年度利润总额、 净利润、扣除非经常性损益后的净利润均为负值且扣除后营业收入低于 3 亿元。 公司已于 2025 年 4 月 29 日对外披露了《关于公司股票交易被实施退市风险警示 暨停牌的公告》（公告编号：2025-023），公司股票于 2025 年 4 月 30 日开市起 被实施退市风险警示。若公司 2025 年度出现《深圳证券交易所股票上市规则 （2025 年修订）》第 9.3.12 条规定的情形，公司股票存在被终止上市的风险。 2. 根据《深圳证券交易所股票上市规则（2025 年修订）》第 9.3.6 条的规 定：上市公司因触及本规则第 9.3.1 条第一款第一项至第三项情形，其股票交易 被实施退市风险警示后，应当在其股票交易被实施退市风险警示当年会计年度结 束后一个月内，披露股票可能被终止上市的风险提示公告，在首次风险提示公告 披露后至年度报告披露前，每十个交易日披露 ...

证券代码：000504 证券简称：*ST生物 公告编号：2026-011 南华生物医药股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 特别提示： 1.本次股东会未出现否决提案的情形； 2.本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： （1）现场会议召开时间：2026年2月12日15:00 （2）网络投票时间：2026年2月12日（星期四）。其中：通过深圳证券交易 所交易系统进行网络投票的具体时间为2026年2月12日9:15-9:25，9:30－11:30， 13:00-15:00；通过互联网投票系统进行网络投票的时间为2026年2月12日 9:15-15:00。 2.会议召开的地点：长沙高新开发区岳麓西大道1698号麓谷科技创新创业园 B1栋三层会议室 3.会议召开的方式：现场表决与网络投票相结合 4.会议召集人：公司第十二届董事会 5.会议主持人：董事长杨云先生 6.会议召开的合法合规性：本次股东会会议召开符合《中华人民共和国公司 法》《中 ...

二○二六年二月 湖南湘军麓和律师事务所 关于南华生物医药股份有限公司 湖南湘军麓和律师事务所 关于南华生物医药股份有限公司 2026 年第一次临时股东会的 法律意见书 湖南湘军麓和律师事务所 HUNAN XIANGJUNLUHE LAW FIRM 2026 年第一次临时股东会的法律意见书 致：南华生物医药股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）和中国证券监督管理委员会发布的 《上市公司股东会规则》（以下简称"《股东会规则》"）、《深圳证券交易所 上市公司股东会网络投票实施细则》（以下简称"《网络投票实施细则》"）等 有关规定，湖南湘军麓和律师事务所（以下简称"本所"）接受南华生物医药股 份有限公司（以下简称"公司"）的聘请，指派陈琳律师、向思律师（以下简称 "本所律师"）出席并见证了公司于 2026 年 2 月 12 日（星期四）15:00 在长沙 高新开发区岳麓西大道1698号麓谷科技创新创业园B1栋三层会议室召开的公司 2026 年第一次临时股东会（以下简称"本次会议"），并依据有关法律、法规、 规范性文件的规定以及《南华生 ...

Core Viewpoint - The A-share market is experiencing a critical phase where companies are engaging in various actions to avoid delisting due to financial indicators, particularly focusing on achieving revenue above 300 million yuan or turning losses into profits, as well as correcting negative net assets [1][2]. Group 1: Financial Indicators and Delisting Risks - The new "National Nine Articles" implemented in January 2025 raised the revenue threshold for delisting from 100 million yuan to 300 million yuan, allowing companies that can exceed this revenue to avoid delisting risks [5]. - Companies like *ST Jinglun and *ST Dongjing are attempting to cross the delisting threshold through various strategies, including revenue boosts, mergers, and asset disposals [2][6]. Group 2: Company Strategies for Survival - *ST Jinglun is trying to incorporate new business lines into its main revenue streams, but faced challenges with revenue recognition for its new server business, leading to a significant reduction in reported revenue [7][8]. - *ST Dongjing reported an expected revenue increase to between 340 million and 370 million yuan, aided by new business ventures, although it still anticipates losses [9][10]. Group 3: Mergers and Acquisitions - Mergers and acquisitions are being utilized by companies like *ST Huazhong and *ST Huike to surpass financial thresholds, with *ST Huazhong projecting a turnaround in profitability due to its acquisition of a controlling stake in Zhejiang Zhuangchen [12][13]. - *ST Huike's acquisition of a 51% stake in Nanjing Yizhengtong is also noted as a strategy to meet revenue requirements, despite market skepticism regarding its financial health [13]. Group 4: Asset Restructuring and Debt Relief - Several companies are opting for asset disposals to improve their financial standings, with *ST Zhongdi successfully turning its net assets positive through significant asset restructuring [16][17]. - Companies like *ST Nanzhi and *ST Lvkang have also engaged in asset sales to achieve similar outcomes, with *ST Nanzhi transferring real estate assets to improve its equity position [17]. Group 5: Bankruptcy and Debt Waivers - Bankruptcy restructuring has emerged as a key strategy for survival, with companies like *ST Dongyi successfully completing their restructuring plans and improving their financial positions [18]. - Debt waivers from major shareholders or creditors have been reported by several companies, allowing them to quickly enhance their net asset status [18].

Core Viewpoint - The A-share market is witnessing a critical "survival race" as companies face delisting risks due to financial indicators set by the new "National Nine Articles," which include negative profit totals, net profits, and insufficient revenue [2][4]. Group 1: Companies Facing Delisting Risks - *ST Jinglun is experiencing a severe decline, with nine consecutive trading days of limit-down, and a significant drop in trading volume to less than 5 million yuan, as it faces delisting expectations [2]. - Other companies like *ST Dongjing and *ST Huarong are attempting various strategies such as asset restructuring and debt waivers to avoid delisting, focusing on key financial indicators like revenue exceeding 300 million yuan or turning net assets positive [2][4]. Group 2: Financial Performance and Strategies - The new regulations increased the revenue threshold for delisting from 100 million yuan to 300 million yuan, prompting companies to strive for this new target to avoid delisting risks [4]. - *ST Jinglun is attempting to incorporate new business lines into its main revenue stream, while *ST Dongjing is projecting a revenue increase to between 340 million and 370 million yuan, surpassing the 300 million yuan threshold [6][8]. Group 3: Specific Company Actions - *ST Jinglun's revenue forecast for 2025 is approximately 338 million yuan, but after excluding non-core business income, the adjusted revenue is only about 86.22 million yuan, indicating a failure to turn a profit [6][7]. - *ST Huarong expects to achieve a net profit of between 6.5 million and 8 million yuan for 2025, aided by a 30% increase in revenue from its subsidiary, which it acquired a larger stake in [10]. Group 4: Market Reactions and Future Outlook - The market is closely monitoring companies that have narrowly met the revenue thresholds, with concerns about the sustainability of these figures and the potential for revenue adjustments post-audit [11][12]. - Companies are increasingly resorting to mergers and acquisitions as a strategy to enhance their financial performance and meet the new revenue requirements [10][15].

证券代码：000504 证券简称：*ST 生物 公告编号：2026-010 南华生物医药股份有限公司 股票可能被终止上市的第二次风险提示公告 公司可能触及的终止上市情形： | 具体情形 | 是否适用 （对可能触及的打勾） | | --- | --- | | 经审计的利润总额、净利润、扣除非经常性损益后 | | | 的净利润三者孰低为负值，且扣除后的营业收入低 | √ | | 于 3 亿元。 | | | 经审计的期末净资产为负值。 | | 1 | 财务会计报告被出具保留意见、无法表示意见或者 | | --- | | 否定意见的审计报告。 | | 追溯重述后利润总额、净利润、扣除非经常性损益 | | 后的净利润三者孰低为负值，且扣除后的营业收入 | | 低于 3 亿元；或者追溯重述后期末净资产为负值。 | | 财务报告内部控制被出具无法表示意见或者否定意 | | 见的审计报告。 | | 未按照规定披露内部控制审计报告，因实施完成破 | | 产重整、重组上市或者重大资产重组按照有关规定 | | 无法披露的除外。 | | 未在法定期限内披露过半数董事保证真实、准确、 | | 完整的年度报告。 | 本公司及董事会全体成 ...

Core Viewpoint - Nanhua Biopharmaceutical Co., Ltd. has officially terminated its major asset restructuring plan after nearly six months of planning due to a lack of consensus among the parties involved in the transaction [1] Group 1: Company Background and Performance Challenges - The company, originally listed as Hong Kong and Macau Industry in 1992, has undergone multiple ownership changes and name changes, finally being renamed Nanhua Biopharmaceutical in 2015 to enter the biomedicine sector [2] - The company has two main businesses: biomedicine (stem cell and immune cell storage) and energy conservation and environmental protection, but its performance has been inconsistent, with revenue still heavily reliant on cell storage [2] - The company has oscillated between being under special treatment (ST) and being delisted, facing continuous losses from 2014 to 2015, leading to its first ST designation in 2016, and again facing ST status in 2019 due to two consecutive years of losses [2] Group 2: Termination of Restructuring and Financial Impact - The company announced the termination of its plan to acquire a 51% stake in Hunan Huize Biopharmaceutical Technology Co., Ltd. due to the inability to reach an agreement on the transaction terms, with the termination not expected to have a significant adverse impact on its operations or financial status [3][4] - The company committed to not planning any major asset restructuring for at least one month following the announcement [4] Group 3: Financial Forecast and Recovery - Alongside the termination announcement, the company projected its 2025 revenue to be between 385 million to 425 million yuan, a significant increase from approximately 130 million yuan in the previous year [5] - The company expects to achieve a net profit attributable to shareholders of between 28.5 million to 32.5 million yuan in 2025, marking a turnaround from a loss of 19.846 million yuan in the same period last year [6] - The recovery is primarily driven by the acquisition of Loudi Jinhong New Materials Co., Ltd., which has enhanced revenue from resource recycling businesses, rather than the terminated biopharmaceutical acquisition [6][7]

Core Viewpoint - Nanhua Biomedical Co., Ltd. has officially terminated its major asset restructuring plan after nearly six months of planning due to a lack of consensus among the parties involved in the transaction [1][7]. Group 1: Company Background and Performance - The company, formerly known as Hong Kong and Macau Industry, was listed in 1992 and has undergone multiple ownership changes and name changes, finally being renamed "Nanhua Biomedical" in 2015 to enter the biomedical field [4]. - The company has two main businesses: "biomedical" (stem cell and immune cell storage) and "energy conservation and environmental protection," but its performance has been inconsistent, with revenue heavily reliant on cell storage [4]. - The company has oscillated between being under special treatment (ST) and being delisted due to continuous losses, with the most recent instance of being under ST occurring in 2019 [4][5]. Group 2: Termination of Restructuring - The planned acquisition of a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. was intended to expand the biomedical sector but was ultimately terminated due to failure to reach an agreement on the transaction plan [6][7]. - The termination of the restructuring will not have a significant adverse impact on the company's production, operations, or financial status, as it was still in the planning stage and had not entered formal implementation [7][8]. Group 3: Financial Performance and Future Outlook - The company has projected a significant increase in revenue for 2025, estimating between 385 million to 425 million yuan, compared to approximately 130 million yuan in the previous year [10]. - The net profit attributable to shareholders is expected to be between 28.5 million to 32.5 million yuan, marking a turnaround from a loss of 19.846 million yuan in the previous year [11]. - The improvement in financial performance is primarily attributed to the acquisition of Loudi Jinhong New Materials Co., Ltd., which has enhanced revenue from resource recycling businesses [13][14]. - The company is also expanding its product offerings related to its biomedical and environmental protection businesses, contributing to revenue and profit growth [15][16].

Group 1 - The company *ST Bio announced that its 12th Board of Directors' eighth meeting was held on January 23, 2026, via telecommunication [1] - The meeting reviewed the proposal to amend the "External Guarantee Management Measures" [1] Group 2 - International gold prices have surpassed $5,000, marking a 280% increase over the past seven years [1] - Experts suggest that the future of gold prices will depend significantly on the U.S. dollar, with a focus on the international monetary system, interest rate cuts, and technological revolutions [1]